Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00583128 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome
A Phase 2 study, sponsored by Ocera Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 117
- Enrollment target
NCT00583128 is a Phase 2 study that has completed, run by Ocera Therapeutics. The registered enrollment target is 117 participants.
The verdict
NCT00583128, a Phase 2 study, has completed, sponsored by Ocera Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 117 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with non-constipating IBS. The study will test whether or not patients receiving AST-120 experience at least a 50% reduction in the number of days with abdominal pain compared to placebo.
Interventions
- DRUG AST-120
- DRUG Celphere® CP-305
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00583128
The ClinicalTrials.gov registry entry for NCT00583128 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ocera Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AST-120 is the first listed.
NCT00583128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00583128 about?
NCT00583128 is a clinical study titled "Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome". The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with non-constipating IBS. The study will test whether or not patients receiving AST-120 experience at least a 50% reduction in the number of days with abdominal pain compare...
What is the current status of trial NCT00583128?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2007-08. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00583128?
The interventions under investigation include: AST-120 (DRUG), Celphere® CP-305 (DRUG).
Who is sponsoring clinical trial NCT00583128?
This trial is sponsored by Ocera Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.